TL;DR
The developed nanoliposomal system offers significant clinical advantages including potential for enhanced tumor targeting, reduced dosing frequency, and minimized systemic toxicity, pending in vivo validation, and improved therapeutic outcomes.
The developed chitosan-coated Eudragit® S100 nanoparticle system represents a promising platform for sustained, colon-targeted oral delivery of HSP and other poorly bioavailable bioactive compounds.
A three-factor, three-level Box–Behnken Design-optimized Wogonin-NL constitutes a physico-chemically well-defined, biologically active nanoliposomal platform with cancer-preferential cytotoxicity and a validated stability profile.
Background: Cisplatin is an effective chemotherapeutic agent; however, its clinical application is limited by poor aqueous solubility, low cellular uptake, and suboptimal biopharmaceutical performance. Nanocrystal technology offers a promising strategy to overcome these limitations by enhancing dissolution and intracel...
Nilotinib is a weakly basic, BCS Class II tyrosine kinase inhibitor with poor aqueous solubility, which may limit its oral bioavailability, particularly at higher gastrointestinal pH. In the present study, a supersaturable self-nanoemulsifying drug delivery system (sSNEDDS) was systematically developed using castor o...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
